Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080544 · ClinicalTrials.gov registry record · Phase 2
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
A Phase 2 study of Alzheimer Disease and Cognitive Decline, sponsored by Neil M Rofsky, MD, MHA.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT04080544 is a Phase 2 study of Alzheimer Disease and Cognitive Decline that has completed, run by Neil M Rofsky, MD, MHA. The registered enrollment target is 125 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04080544, a Phase 2 study of Alzheimer Disease and Cognitive Decline, has completed, sponsored by Neil M Rofsky, MD, MHA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 (\[18F\]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden to cognitive function and amyloid deposition collected over the previous 10-year interval.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- DRUG [18F]AV-1451
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080544
The ClinicalTrials.gov registry entry for NCT04080544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (95% lower). The listed sponsor is Neil M Rofsky, MD, MHA, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography is the first listed.
NCT04080544 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04080544 about?
NCT04080544 is a clinical study titled "Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study". The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 (\[18F\]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden t...
What is the current status of trial NCT04080544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2019-01-15. Estimated completion is 2022-06-30.
What conditions does trial NCT04080544 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Decline.
What interventions are being tested in trial NCT04080544?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), [18F]AV-1451 (DRUG).
Who is sponsoring clinical trial NCT04080544?
This trial is sponsored by Neil M Rofsky, MD, MHA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04080544 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.